Weixiu Luo

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Olivia Pagani, Meredith M. Regan, Barbara Walley et al. · New England Journal of Medicine · 2014 · 738 citations · Full text

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 578 citations · Full text

Combination Cediranib, Medicine, Olaparib Versus Olaparib +9

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 258 citations

Epithelial Ovarian Cancer, Medicine, Pharmacology +8

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer

Joyce F. Liu, Christina I. Herold, Kathryn P. Gray et al. · JAMA Oncology · 2019 · 218 citations · Full text

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Panagiotis A. Konstantinopoulos, Weixiu Luo, Joyce F. Liu et al. · Journal of Clinical Oncology · 2019 · 211 citations · Full text